Optimizing platelet transfusion thresholds based on TEG maximum clot strength (MA value) to reduce platelet usage and improve patient outcomes in liver transplantation: a cohort study

基于TEG最大凝块强度(MA值)优化血小板输注阈值,以减少血小板用量并改善肝移植患者预后:一项队列研究

阅读:1

Abstract

BACKGROUND: Liver transplantation (LT) is a highly complex procedure often requiring substantial blood product transfusions. Conventional platelet transfusion practices rely on static platelet count thresholds, potentially leading to overuse and associated risks. Thromboelastography (TEG) offers dynamic assessment of clotting, particularly through the Maximum Clot Strength (MA) value, which may optimize platelet transfusion thresholds and improve outcomes. METHODS: This retrospective cohort study analyzed 231 patients who underwent LT between January 2019 and December 2023. Patients were divided into the TEG group (n = 103) receiving platelet transfusions guided by TEG MA values < 55 mm, and the conventional platelet count transfusion (CPCT) group (n = 128) with transfusions based on platelet counts < 50 × 10(9)/L. TEG was performed using kaolin-activated citrated whole blood samples. Propensity score matching was employed to control for potential confounders. Both groups were compared for platelet usage, postoperative outcomes, and quality of life (QOL) assessed via the SF-36 survey at 1 month post-surgery. RESULTS: After propensity matching, the TEG group demonstrated significant reductions in platelet transfusions on postoperative days 1 and 3 compared to the CPCT group (36.9 vs. 61.7% on day 1, P < 0.001; 5.8 vs. 19.5% on day 3, P = 0.002). No significant differences were observed in red blood cell or plasma transfusions. The TEG group experienced enhanced postoperative QOL, with higher scores in Physical Functioning, Role-Physical, General Health, Vitality, Social Functioning, and Role-Emotional (P < 0.05 for each domain). No significant differences were observed in mortality or major complications between groups. CONCLUSION: Implementing TEG-guided platelet transfusion strategies in LT significantly reduces platelet use and improves patient QOL by providing real-time functional hemostasis assessments.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。